metformin has been researched along with Anterior Circulation Transient Ischemic Attack in 7 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We aimed to assess the feasibility, safety and effects on glucose metabolism of metformin or sitagliptin in patients with transient ischaemic attack (TIA) or minor ischaemic stroke and IGT." | 9.41 | Safety, feasibility and efficacy of metformin and sitagliptin in patients with a TIA or minor ischaemic stroke and impaired glucose tolerance. ( Brouwers, PJAM; den Hertog, H; Dippel, DWJ; Koudstaal, P; Lingsma, H; Mulder, LJMM; Osei, E; Zandbergen, A, 2021) |
| "We aimed to assess the safety, feasibility, and effects on glucose metabolism of treatment with metformin in patients with TIA or minor ischemic stroke and impaired glucose tolerance." | 9.20 | Safety and feasibiLIty of Metformin in patients with Impaired glucose Tolerance and a recent TIA or minor ischemic stroke (LIMIT) trial - a multicenter, randomized, open-label phase II trial. ( Achterberg, S; Algra, A; den Hertog, HM; Dippel, DW; Kappelle, LJ; Koudstaal, PJ; Vermeer, SE; Zandbergen, AA, 2015) |
| "The Metformin and sitAgliptin in patients with impAired glucose tolerance and a recent TIA or minor ischemic Stroke trial (MAAS trial) is a phase II, multicenter, randomized, controlled, open-label trial with blinded outcome assessment." | 9.20 | Metformin and sitAgliptin in patients with impAired glucose tolerance and a recent TIA or minor ischemic Stroke (MAAS): study protocol for a randomized controlled trial. ( Brouwers, PJ; den Hertog, HM; Dippel, DW; Fonville, S; Koudstaal, PJ; Lingsma, HF; Mulder, LJ; Osei, E; Zandbergen, AA, 2015) |
| "We aimed to assess the feasibility, safety and effects on glucose metabolism of metformin or sitagliptin in patients with transient ischaemic attack (TIA) or minor ischaemic stroke and IGT." | 5.41 | Safety, feasibility and efficacy of metformin and sitagliptin in patients with a TIA or minor ischaemic stroke and impaired glucose tolerance. ( Brouwers, PJAM; den Hertog, H; Dippel, DWJ; Koudstaal, P; Lingsma, H; Mulder, LJMM; Osei, E; Zandbergen, A, 2021) |
| "We aimed to assess the safety, feasibility, and effects on glucose metabolism of treatment with metformin in patients with TIA or minor ischemic stroke and impaired glucose tolerance." | 5.20 | Safety and feasibiLIty of Metformin in patients with Impaired glucose Tolerance and a recent TIA or minor ischemic stroke (LIMIT) trial - a multicenter, randomized, open-label phase II trial. ( Achterberg, S; Algra, A; den Hertog, HM; Dippel, DW; Kappelle, LJ; Koudstaal, PJ; Vermeer, SE; Zandbergen, AA, 2015) |
| "The Metformin and sitAgliptin in patients with impAired glucose tolerance and a recent TIA or minor ischemic Stroke trial (MAAS trial) is a phase II, multicenter, randomized, controlled, open-label trial with blinded outcome assessment." | 5.20 | Metformin and sitAgliptin in patients with impAired glucose tolerance and a recent TIA or minor ischemic Stroke (MAAS): study protocol for a randomized controlled trial. ( Brouwers, PJ; den Hertog, HM; Dippel, DW; Fonville, S; Koudstaal, PJ; Lingsma, HF; Mulder, LJ; Osei, E; Zandbergen, AA, 2015) |
| "312,368 persons with newly diagnosed type 2 diabetes without previous stroke/TIA (mean age: 64 years; 52% males) were included." | 1.72 | Association of glucose-lowering drugs with incident stroke and transient ischaemic attacks in primary care patients with type 2 diabetes: disease analyzer database. ( Kostev, K; Rathmann, W, 2022) |
| "Pretreatment with liraglutide in diabetic and non-diabetic animals reduced infarct size as compared to controls, while only non-diabetic liraglutide-treated rats presented neurologic deficit decreases." | 1.48 | Neuroprotective effect of glucagon-like peptide-1 receptor agonist is independent of glycaemia normalization in type two diabetic rats. ( Chefu, S; Filchenko, I; Kolpakova, M; Simanenkova, A; Vlasov, T, 2018) |
| "Pretreatment by metformin increased the level of Nrf2 and heme oxygenase-1 in the hippocampus of ischemic rats compared with untreated ischemic group." | 1.42 | Pre-treatment with metformin activates Nrf2 antioxidant pathways and inhibits inflammatory responses through induction of AMPK after transient global cerebral ischemia. ( Ashabi, G; Goudarzvand, M; Khalaj, L; Khodagholi, F; Sarkaki, A, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (14.29) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (57.14) | 24.3611 |
| 2020's | 2 (28.57) | 2.80 |
| Authors | Studies |
|---|---|
| Osei, E | 2 |
| Zandbergen, A | 1 |
| Brouwers, PJAM | 1 |
| Mulder, LJMM | 1 |
| Koudstaal, P | 1 |
| Lingsma, H | 1 |
| Dippel, DWJ | 1 |
| den Hertog, H | 1 |
| Rathmann, W | 1 |
| Kostev, K | 1 |
| Filchenko, I | 1 |
| Simanenkova, A | 1 |
| Chefu, S | 1 |
| Kolpakova, M | 1 |
| Vlasov, T | 1 |
| den Hertog, HM | 2 |
| Vermeer, SE | 1 |
| Zandbergen, AA | 2 |
| Achterberg, S | 1 |
| Dippel, DW | 2 |
| Algra, A | 1 |
| Kappelle, LJ | 1 |
| Koudstaal, PJ | 2 |
| Ashabi, G | 1 |
| Khalaj, L | 1 |
| Khodagholi, F | 1 |
| Goudarzvand, M | 1 |
| Sarkaki, A | 1 |
| Fonville, S | 1 |
| Brouwers, PJ | 1 |
| Mulder, LJ | 1 |
| Lingsma, HF | 1 |
| Rubenstein, AH | 1 |
3 trials available for metformin and Anterior Circulation Transient Ischemic Attack
| Article | Year |
|---|---|
Safety, feasibility and efficacy of metformin and sitagliptin in patients with a TIA or minor ischaemic stroke and impaired glucose tolerance.
Topics: Blood Glucose; Brain Ischemia; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combina | 2021 |
Safety and feasibiLIty of Metformin in patients with Impaired glucose Tolerance and a recent TIA or minor ischemic stroke (LIMIT) trial - a multicenter, randomized, open-label phase II trial.
Topics: Blood Glucose; Female; Humans; Hypoglycemic Agents; Ischemic Attack, Transient; Male; Metformin; Mid | 2015 |
Metformin and sitAgliptin in patients with impAired glucose tolerance and a recent TIA or minor ischemic Stroke (MAAS): study protocol for a randomized controlled trial.
Topics: Biomarkers; Blood Glucose; Clinical Protocols; Feasibility Studies; Glucose Intolerance; Glucose Tol | 2015 |
4 other studies available for metformin and Anterior Circulation Transient Ischemic Attack
| Article | Year |
|---|---|
Association of glucose-lowering drugs with incident stroke and transient ischaemic attacks in primary care patients with type 2 diabetes: disease analyzer database.
Topics: Cholesterol; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Glucagon-Like Pe | 2022 |
Neuroprotective effect of glucagon-like peptide-1 receptor agonist is independent of glycaemia normalization in type two diabetic rats.
Topics: Animals; Blood Glucose; Brain; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Glucagon- | 2018 |
Pre-treatment with metformin activates Nrf2 antioxidant pathways and inhibits inflammatory responses through induction of AMPK after transient global cerebral ischemia.
Topics: AMP-Activated Protein Kinases; Animals; Antioxidants; Enzyme Induction; Inflammation Mediators; Isch | 2015 |
A 64-year-old man with adult-onset diabetes.
Topics: Angiotensin-Converting Enzyme Inhibitors; Blood Glucose Self-Monitoring; Carotid Stenosis; Decision | 1996 |